Every 8-K that Entero Therapeutics (ENTO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ENTO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ENTO filings page.
GridAI Technologies Corp. entered a Debt Settlement and Subscription Agreement with its lender to resolve a default under a revolving loan. The lender had demanded $1,014,675 after the January 31, 2026 maturity passed without repayment. GridAI will pay $800,000 in cash, covering $700,000 of principal and $100,000 of accrued interest, and will issue 71,482 common shares at a deemed price of $3.25 per share to satisfy remaining accrued interest of $232,315.
GridAI Technologies Corp. entered into two private placement financings to raise equity-linked capital. A $2.54 million financing will issue 74,000 common shares, Pre-Funded Warrants for 1,196,001 shares, and Common Warrants for 1,270,001 shares at a combined purchase price of $2.00 per share or Pre-Funded Warrant plus Common Warrant. A separate $5.25 million financing will issue 87,260 common shares, Pre-Funded Warrants for 1,745,199 shares, and Common Warrants for 1,832,459 shares at $2.865 per unit, with 20% of proceeds paid at closing and 80% upon SEC effectiveness of a resale registration statement. All Pre-Funded Warrants are exercisable at $0.00001 per share with no expiration, and the related Common Warrants carry multi-year terms and specified exercise prices, subject to beneficial ownership limits and customary registration rights.
GridAI Technologies Corp. reported that it has regained compliance with Nasdaq listing requirements after a brief filing delay. Nasdaq had notified the company on April 22, 2026 that it was not in compliance with Listing Rule 5250(c)(1) because its Form 10-K for the period ended December 31, 2025 was late. GridAI filed the Form 10-K on May 1, 2026, and on May 4, 2026 Nasdaq confirmed the company was back in compliance and closed the matter.
GridAI Technologies Corp. reported receiving a notice from Nasdaq on April 22, 2026 stating it is not in compliance with Listing Rule 5250(c)(1) because its Form 10-K for the year ended December 31, 2025 has not yet been filed. The company has until June 22, 2026 to submit a plan to regain compliance, and Nasdaq may grant an extension through October 12, 2026 if the plan is accepted. GridAI attributes the delay to complexity in reviewing the accounting treatment and other information related to its recent acquisition of Grid AI Corp. The company plans to file the 10-K as soon as possible and submit a compliance plan, but cautions there is no assurance Nasdaq will accept the plan or that it will maintain compliance with Nasdaq requirements in the future.
GridAI Technologies Corp. reports a default-related demand under its Revolving Loan Agreement. The company’s lender sent a demand letter on April 1, 2026, asserting that the loan matured unpaid on January 31, 2026, and seeking $1,014,675, including $700,000 principal, accrued interest, and a 20% default increase. GridAI is evaluating the impact and is in active discussions with the lender.
GridAI Technologies Corp. filed an amended report to provide full historical financials, pro forma results, business description, and risk factors for its acquisition of Grid AI Corp. Grid AI generated only $138,697 of revenue from inception through September 30, 2025 but recorded a net loss of $5,251,751 and a total deficit of $6,521,829. The auditor and management both highlight substantial doubt about Grid AI’s ability to continue as a going concern, citing limited cash of about $333,000, negative working capital, and significant obligations including $7,000,000 of deferred consideration. Pro forma for the acquisition, the combined company reports a net loss of $10,589,048 for the period ended September 30, 2025. The filing also describes a strategic pivot away from legacy residential energy platforms toward an early-stage AI data center energy orchestration platform that has not yet been commercially deployed, along with extensive competitive and execution risks.
GridAI Technologies Corp. completed a previously agreed rescission transaction involving ImmunogenX, LLC on December 31, 2025. Under this deal, the company transferred to the former ImmunogenX, Inc. shareholders all of the membership interests of ImmunogenX, LLC that it held, so ImmunogenX, LLC is no longer a subsidiary and the company no longer owns any interest in it.
The company notes that this disposition is considered a significant asset sale for reporting purposes, and it has filed unaudited pro forma consolidated financial statements as an exhibit to show how the transaction would have affected its historical financials.
Entero Therapeutics (ENTO) reported that on October 17, 2025, the stockholders of GridAI Corp waived their right to appoint two directors to Entero’s Board as provided in Section 5.09 of the Share Exchange Agreement dated September 30, 2025. The waiver remains in effect until Entero’s shareholders approve the appointment of such directors at a duly called meeting in accordance with applicable laws.
This update follows the previously disclosed agreement referenced in the company’s October 6, 2025 filing and reflects a governance step that defers board appointments pending shareholder approval.
Entero Therapeutics (ENTO) reported that Nasdaq has confirmed the company is back in compliance with the minimum stockholders’ equity requirement under Listing Rule 5550(b)(1). Compliance was affirmed in a letter dated October 28, 2025, following Entero’s October 6 disclosure tied to a September 30 share exchange with GridAI.
The company had previously fallen out of compliance after reporting stockholders’ equity of ($3,876,738) as of December 31, 2024, below the $2.5 million minimum. Nasdaq had granted an extension through October 8, 2025, to regain compliance. Nasdaq cautioned that if Entero does not evidence compliance in its next periodic report, the company may face delisting, with the option to appeal to a Hearings Panel.
Entero Therapeutics entered a Securities Purchase Agreement allowing a private placement of up to $5,000,000 in promissory notes and a common stock purchase warrant for up to 1,520,000 shares, with subsequent closings permitted.
At the initial closing on October 17, 2025, the company received $500,000 in gross proceeds by issuing a $500,000 non‑interest‑bearing, non‑convertible Note maturing one year and one day from issuance, which the company may extend in one‑year‑and‑one‑day increments. It also issued a Warrant to purchase up to 200,000 shares at an exercise price of $2.50 per share, exercisable upon stockholder approval and expiring five years after that approval.
The Warrant size may adjust pro rata with additional investments, up to 1,520,000 shares, includes a 4.9% Beneficial Ownership Limitation, and may be exercised cashlessly if the underlying shares are not registered. Entero plans to use proceeds for general corporate purposes, and will seek stockholder approval and file a registration statement for the resale of the Warrant shares.
Entero Therapeutics, Inc. filed a Form 8-K reporting several exhibits tied to a material corporate action. The company filed a Certificate of Designation establishing Series H Non-Voting Convertible Preferred Stock with the Delaware Secretary of State on October 1, 2025. The filing also lists a Form of Registration Rights Agreement, a Share Exchange Agreement, and a Press Release dated October 1, 2025 as exhibits. The cover page interactive XBRL is included. The Form 8-K is signed by Jason D. Sawyer as Interim Chief Executive Officer on October 6, 2025, indicating the company provided contemporaneous disclosure of these actions.